Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did you see the volume and price action today. Amazing. Excited to see where this goes in the next few weeks. Goal .40$
Hope you got in last time. You saw the action today. I think this just the start. Wish more people would come here chat about wuhn.
of course not, the new ceo is Donald Hunter
Psychedelics and Cannabinoids Ongoing Research
Newsletter May 15, 2020
It's time we get back to our roots: Nature’s plant-based medicines, Magic Mushrooms and their psychoactive ingredient – psilocybin.
What are magic mushrooms and psilocybin
Psilocybin is a classic hallucinogenic compound produced by over 100 species of mushrooms. It has a strong effect on serotonin receptors in the brain, including some in the cerebral cortex and thalamus regions.
Psilocybin mushrooms also have some powerful therapeutic benefits. Researchers are diving into their potential to treat numerous disorders. Areas of interest include conditions like mood disorders, anxiety, OCD, and addiction.
Legality
Currently, psilocybin-containing mushrooms are illegal in the United States and are listed as a Schedule 1 drug. Even mushroom spores, which don’t contain any psychoactive chemicals yet, are illegal in many states. A few cities – Denver, Oakland and Santa Cruz – have decriminalized mushrooms, meaning you won’t get arrested for possessing them but there are no legal avenues through which to purchase or sell them either. Oregon has plans to legalize mushrooms entirely, however, these plans have been put on the back-burner amid the current pandemic.
Potential Medical Benefits
Although there are many possible uses for psilocybin, at the moment, it’s most frequently used to treat conditions relating to mental health. Depression, PTSD and anxiety are among the most researched indications for psilocybin treatment.
Another possible use for psychedelic mushrooms is in the cessation of smoking, alcoholism, and other addictions.
It’s also being looked at as a possible treatment for certain types of cancers, heart disease, inflammation, and many other conditions.
Understanding exactly how psilocybin works will help discover and develop the best treatments to help patients.
Psychedelic Research and Clinical trial?
Our collaborative work with scientists from the Pretoria University of South Africa gives a significant boost to research into the chemistry and pharmacology of psychedelics.
Our ongoing magic mushroom psilocybin clinical trial:
‘’Isolation of psilocybin from genus of Psilocybe and Panaeolus mushroom extracts and investigating their micro-dosing effects and their underlying mechanisms towards depression and the cardiovascular risks in vivo on rats and in vitro on cell lines.’’
(2018-2020)
The study aims to investigate the effect of different drying methods on the extract composition and the differences in concentration levels of psilocybin in four magic mushroom species (Panaeolus cyanescens, Psilocybe natalensis, Psilocybe cubensis A+ strain and Psilocybe cubensis). The effect of micro-dosing psilocybin mushrooms on depression and the underlying effect of psilocybin on nerve conduction and cardiac excitability, and finally the micro-dosing effects of psilocybin towards depression and its cardiovascular effect in vivo on Wistar normotensive rats and in vitro on the 5-HT2B serotonin receptor cell line, a cardiac-myoblast cell line, animal and human endothelial cell line.
The in vitro and in vivo animal studies were successfully concluded, and results are being compiled and the findings to be published mid-year and expected to be presented at a conference for cardiology in September this year.
With our remarkable results, the protocol for phase I human trial is now being set and is scheduled to begin late 2020 or early 2021.
Our objective is to develop intellectual proprietary focused on psilocybin and psychedelic medical research for medical applications like drug and alcohol addiction, mental disorder, depression and commercialization of such IP.
Some Next Steps?
Wuhan is looking at how certain blends of cannabinoids, plant-based medicine, and mushrooms could effectively treat a variety of chronic and inflammatory medical conditions like colon cancer, IBS and cardiovascular disease. We plan to start clinical trials with cannabinoids in early 2021.
The Wuhan Team wishes everybody all the very best in health and happiness.
Sincerely,
Dr. Anna Morera Leralta
News on psilocybin clinical trial
Wuhan's #Psychedelics and #Cannabinoids Ongoing #Research
https://t.co/aQdO7kgcqT
$wuhn
https://t.co/rXikA7bslU
management was able to remove restrictions on the stock last Friday -Etrade and TD - I think that is why the stock suffered down trend before. That's why we see green now. I think management delayed all pr's until they got this lifted. now that it is, we should expect a lot of news coming in and much action.
wuhn is a hidden gem about to be discovered by all.
I believe more eye are on wuhn. no way we stay at this level. Market cap is way to low if you think about it: $2 million They are in clinical trial who is about to start phase 1 human trials, so ask yourself, most bio company would be at $30-50 million market cap minimum.
Broke the 50sma yesterday. Next is the 200sma at .078
This is going to be the best stock investment for 2020.
I did. He has no say on anything regarding the business anymore.
He owns restricted shares and will get some cash 40k later to refund some of the expenses of the company.
He has the right to sell Kush cakes if he wants like any other distributor. Nothing special about that.
please share where you see he is still involved and in what capacity. thanks
Get your facts right - he is not - talked to the new ceo.
He is gone. Got a severance package for leaving the company.
Very sure as per new ceo said.
Marco is gone, only got a severance package for leaving.
That's why the company was waiting for before issuing news.imo
Everyone can buy the stock now.
Investors @WGG_Company $WUHN were asking about restrictions on buying shares online without having to call in the order at a couple of online trading houses. From what we can see, the restrictions have been lifted. Maybe a sign of great things to come??? #stockstowatch #Invest?? https://t.co/G77mQx1zlv
You can buy on etrade now
I would buy more at these level. I dont think will see them ever again. Just talk to him. You wont regret it.
jeff@mjmedtech.com
Very cool and transparent ceo.
For many reasons:
- They havent for a long time, but will soon per the CEO
- every year the stock runs around this time of the year.
- Stock is oversold
- gut feeling :)
$dewm waking up - bid growing. news leaked maybe
Probably they got the financing.
I would keep an eye for news, once it hits, we will be at .10$
really believe this will go to 1$.
they are old warrant?
Ask is getting taken out at .03, reversal coming
Great news 8k legitimise the PR's and no SEC suspension like other scam codvid 19 wanna be stock.
This will bring a lot of attention. Approval coming soon.
Psychedelics stock WUHN under the radar - COMPANY JUST SENT OUT THEIR CORPORATE PRESENTATION
https://mailchi.mp/f167348365cf/wuhn-covid-2612828?e=cc8b31a655
https://wuhn.org/wp-content/uploads/2020/04/Wuhan-Corporate-Presentation-15-April-2020.pdf
Psychedelics stock WUHN under the radar - COMPANY JUST SENT OUT THEIR CORPORATE PRESENTATION
https://mailchi.mp/f167348365cf/wuhn-covid-2612828?e=cc8b31a655
https://wuhn.org/wp-content/uploads/2020/04/Wuhan-Corporate-Presentation-15-April-2020.pdf
Psychedelics stock WUHN under the radar - COMPANY JUST SENT OUT THEIR CORPORATE PRESENTATION
https://mailchi.mp/f167348365cf/wuhn-covid-2612828?e=cc8b31a655
https://wuhn.org/wp-content/uploads/2020/04/Wuhan-Corporate-Presentation-15-April-2020.pdf
Psychedelics stock WUHN under the radar - COMPANY JUST SENT OUT THEIR CORPORATE PRESENTATION
https://mailchi.mp/f167348365cf/wuhn-covid-2612828?e=cc8b31a655
https://wuhn.org/wp-content/uploads/2020/04/Wuhan-Corporate-Presentation-15-April-2020.pdf
WUHN Corporate presentation out! Amazing stuff
https://mailchi.mp/f167348365cf/wuhn-covid-2612828?e=cc8b31a655
https://wuhn.org/wp-content/uploads/2020/04/Wuhan-Corporate-Presentation-15-April-2020.pdf
They are changing the name anyway. Its just bad luck - who knew!
He has no problem getting the money - I am sure of that. You got to take in consideration the unforeseen circumstances that coronavirus is causing. Most people are quarantine at home. So very little can happen while this is still on.
Got some 19's - fully loaded and ready for FDA News
NICE. News coming this week as per ceo. Check post on twitter.
5 million non toxic financing gets pps over 1 penny, even higher. In a matter of days. What do you think pps will be once we get news about financing is done.
yes, they are - actually very soon.
I agree - this is a multiple day runner
got myself some 22's and 23's today. Just need FDA news and we are in penny land.
I think management is waiting to get financing - without it, they can't execute their plan. cononavirus must have delayed things. Better for us. will try to get more 4's next week.
what would you like to know?
they have a lot happening - what interest me the most is the clinical trial with psilocybin and the research with CBD.
From what I got from our conversation, the in vivo and in vitro testing is done with amazing results. Not public yet because they want to patent the discovery. Also they are starting human trial this year for alcohol addiction with assisted-treatment with psilocybin and other study.
psychedelics stock are hot these days - just a matter of time.
I talked to Jeff the CEO - you can chat with him if you want - he is actually a cool guy - just email him at jeff@mjmedtech.com
the bid is getting stronger every day - I believe one day, we will see this pop like crazy - so much happening behind the scene.